Brands Browse Interactions Pill ID Categories

Loading…

Drugvu is an independent compilation of publicly-disclosed pharmaceutical regulatory information. It is not affiliated with the FDA, EMA, MHRA, Health Canada, TGA, TİTCK, PMDA, or any pharmaceutical manufacturer or regulatory agency.

This is not medical advice. Always consult a qualified healthcare professional for medical decisions.

About Editorial process Editorial team Data sources Methodology Corrections Contribute Privacy Terms DMCA Contact

Panitumumab and Idelalisib: Moderate Interaction - Drugvu

🏠›Panitumumab›Interaction with Idelalisib

Panitumumab + Idelalisib

Drug interaction

Moderate interaction

A moderate drug-drug interaction between Panitumumab and Idelalisib is recorded in public interaction data. Severity reflects the source classification; it does not describe your individual risk. Do not start, stop, or change either medicine based on this page.

What “moderate” means

A moderate interaction can matter in some people. The combination is sometimes used, but usually with caution - monitoring, timing changes, or dose adjustments.

What to do

Mention this combination to your pharmacist or prescriber. Do not stop either medicine without advice.

The two medicines

Active ingredient

Panitumumab

Egfr (Epidermal Growth Factor Receptor) Inhibitors

Uses, side effects, dosage →· 21 recorded interactions

Active ingredient

Idelalisib

Phosphatidylinositol-3-Kinase (Pi3k) Inhibitors

Uses, side effects, dosage →· 624 recorded interactions

Source

DDInter 2.0 (CC-BY 4.0, https://ddinter.scbdd.com)

This is not medical advice. Drugvu is an independent aggregator of public records.